Rapamycin-rather than FK506-might promote allograft tolerance induced by CD4+CD25+ regulatory T cells

Surgery

Volumn 146, Issue 3, 2009, Pages 526-527

  Du, Jun Feng ^a   Li, Shi Yong ^a   Yu, Bo ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYTOKINE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; RAPAMYCIN; TACROLIMUS; TRANSCRIPTION FACTOR FOXP3;

ALLOGRAFT; ANIMAL EXPERIMENT; ANIMAL MODEL; CD4+ CD25+ T LYMPHOCYTE; CHRONIC ALLOGRAFT VASCULOPATHY; CHRONIC GRAFT REJECTION; CYTOKINE RELEASE; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LETTER; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADOPTIVE TRANSFER; ANIMALS; APOPTOSIS; CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TACROLIMUS; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 68949206324     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2009.02.007     Document Type: Letter

References (16)

1. + regulatory T cells ameliorates rejection of DA-to-Lewis rat liver transplantation. Surgery 142 (2007) 67-73
2. + regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 108 (2006) 390-399
3. Vincenti F., Jensik S.C., Filo R.S., Miller J., and Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 73 (2002) 775-782
4. Blaha P., Bigenzahn S., Koporc Z., Schmid M., Langer F., Selzer E., et al. The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade. Blood 101 (2003) 2886-2893
5. Wood K.J., and Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003) 199-210
6. Abraham R.T., and Wiederrecht G.J. Immunopharmacology of rapamycin. Annu Rev Immunol 14 (1996) 483-510
7. Li Y., Li X.C., Zheng X.X., Wells A.D., Turka L.A., and Strom T.B. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 5 (1999) 1298-1302
8. Allen A., Zheng Y., Gardner L., Safford M., Horton M.R., and Powell J.D. The novel cyclophilin binding compound, sanglifehrin A, disassociates G1 cell cycle arrest from tolerance induction. J Immunol 172 (2004) 4797-4803
9. Powell J.D., Lerner C.G., and Schwartz R.H. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 162 (1999) 2775-2784
10. Battaglia M., Stabilini A., and Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 105 (2005) 4743-4748
11. Qu Y., Zhang B., Zhao L., Liu G., Ma H., Rao E., et al. The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol 17 (2007) 153-161
12. Baan C.C., van der Mast B.J., Klepper M., Mol W.M., Peeters A.M., Korevaar S.S., et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation 80 (2005) 110-117
13. Poon M., Marx S.O., Gallo R., Badimon J.J., Taubman M.B., and Marks A.R. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98 (1996) 2277-2283
14. Marx S.O., Jayaraman T., Go L.O., and Marks A.R. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 76 (1995) 412-417
15. Marx S.O., and Marks A.R. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 104 (2001) 852-855
16. Mancini D., Pinney S., Burkhoff D., LaManca J., Itescu S., Burke E., et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 108 (2003) 48-53